Tissue | Expression Dynamics | Abbreviation |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/DCLK1_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/DCLK1_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/DCLK1_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00181056 | Lung | IAC | peptidyl-serine phosphorylation | 69/2061 | 315/18723 | 1.48e-08 | 1.87e-06 | 69 |
GO:00182095 | Lung | IAC | peptidyl-serine modification | 70/2061 | 338/18723 | 1.23e-07 | 1.10e-05 | 70 |
GO:00163586 | Lung | IAC | dendrite development | 55/2061 | 243/18723 | 1.35e-07 | 1.18e-05 | 55 |
GO:00605605 | Lung | IAC | developmental growth involved in morphogenesis | 52/2061 | 234/18723 | 5.39e-07 | 3.32e-05 | 52 |
GO:00160496 | Lung | IAC | cell growth | 89/2061 | 482/18723 | 6.10e-07 | 3.67e-05 | 89 |
GO:00485885 | Lung | IAC | developmental cell growth | 49/2061 | 234/18723 | 6.67e-06 | 2.43e-04 | 49 |
GO:00488134 | Lung | IAC | dendrite morphogenesis | 34/2061 | 146/18723 | 1.68e-05 | 4.79e-04 | 34 |
GO:00486755 | Lung | IAC | axon extension | 29/2061 | 120/18723 | 3.29e-05 | 8.29e-04 | 29 |
GO:19901384 | Lung | IAC | neuron projection extension | 37/2061 | 172/18723 | 4.69e-05 | 1.08e-03 | 37 |
GO:00615646 | Lung | IAC | axon development | 78/2061 | 467/18723 | 1.12e-04 | 2.15e-03 | 78 |
GO:00074096 | Lung | IAC | axonogenesis | 71/2061 | 418/18723 | 1.33e-04 | 2.48e-03 | 71 |
GO:00161976 | Lung | IAC | endosomal transport | 43/2061 | 230/18723 | 3.53e-04 | 5.50e-03 | 43 |
GO:00096156 | Lung | IAC | response to virus | 61/2061 | 367/18723 | 6.75e-04 | 9.12e-03 | 61 |
GO:0001764 | Lung | IAC | neuron migration | 31/2061 | 156/18723 | 7.89e-04 | 1.02e-02 | 31 |
GO:00345047 | Lung | IAC | protein localization to nucleus | 50/2061 | 290/18723 | 8.71e-04 | 1.11e-02 | 50 |
GO:00219552 | Lung | IAC | central nervous system neuron axonogenesis | 11/2061 | 35/18723 | 9.48e-04 | 1.15e-02 | 11 |
GO:00309002 | Lung | IAC | forebrain development | 61/2061 | 379/18723 | 1.52e-03 | 1.61e-02 | 61 |
GO:0021954 | Lung | IAC | central nervous system neuron development | 18/2061 | 81/18723 | 2.68e-03 | 2.46e-02 | 18 |
GO:001810514 | Oral cavity | EOLP | peptidyl-serine phosphorylation | 84/2218 | 315/18723 | 3.32e-13 | 1.05e-10 | 84 |
GO:001820914 | Oral cavity | EOLP | peptidyl-serine modification | 87/2218 | 338/18723 | 1.07e-12 | 2.46e-10 | 87 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
DCLK1 | SNV | Missense_Mutation | novel | c.1243N>A | p.Glu415Lys | p.E415K | O15075 | protein_coding | tolerated(0.1) | benign(0.34) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
DCLK1 | SNV | Missense_Mutation | novel | c.1162G>C | p.Glu388Gln | p.E388Q | O15075 | protein_coding | tolerated(0.21) | benign(0.059) | TCGA-BH-A0B6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
DCLK1 | SNV | Missense_Mutation | | c.2125N>A | p.Tyr709Asn | p.Y709N | O15075 | protein_coding | tolerated_low_confidence(0.3) | benign(0.005) | TCGA-E2-A1AZ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
DCLK1 | SNV | Missense_Mutation | | c.178C>T | p.Arg60Cys | p.R60C | O15075 | protein_coding | deleterious(0.02) | benign(0.151) | TCGA-E2-A1B0-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | SD |
DCLK1 | SNV | Missense_Mutation | | c.913N>G | p.Ser305Gly | p.S305G | O15075 | protein_coding | tolerated(0.14) | possibly_damaging(0.496) | TCGA-EW-A1IZ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | taxotere | SD |
DCLK1 | insertion | Frame_Shift_Ins | novel | c.531_532insCTCTTGGG | p.Glu178LeufsTer21 | p.E178Lfs*21 | O15075 | protein_coding | | | TCGA-BH-A0B8-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | SD |
DCLK1 | insertion | Nonsense_Mutation | novel | c.529_530insTAATTCTAATCTGAAGTAAAAATAATTTGGTC | p.Arg177LeufsTer5 | p.R177Lfs*5 | O15075 | protein_coding | | | TCGA-BH-A0B8-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | SD |
DCLK1 | SNV | Missense_Mutation | rs769128085 | c.989C>T | p.Ser330Leu | p.S330L | O15075 | protein_coding | deleterious(0.02) | possibly_damaging(0.747) | TCGA-MA-AA42-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD |
DCLK1 | SNV | Missense_Mutation | novel | c.194N>C | p.Gly65Ala | p.G65A | O15075 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-VS-A950-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD |
DCLK1 | SNV | Missense_Mutation | novel | c.1103A>C | p.Asn368Thr | p.N368T | O15075 | protein_coding | tolerated(0.58) | benign(0.006) | TCGA-VS-A9V4-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |